GT Biopharma (GTBP) vs Lantern Pharma (LTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed Lantern Pharma (LTRN) over the past year, gaining 789.5% versus a loss of 82.4%. Over five years, LTRN leads with a -91.9% price change compared with -96.3% for GTBP. Lantern Pharma is the larger company by market cap ($12.1 million vs $12.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GTBP | LTRN |
|---|---|---|
| Share price | $6.68 | $0.8127 |
| Market cap | $12.05M | $12.14M |
| 1-day change | +12.27% | -2.08% |
| YTD return | +750.96% | -73.18% |
| 1-year return | +789.48% | -82.41% |
| 5-year return | -96.32% | -91.88% |
| EPS (TTM) | $-161.13 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.75 | $4.68 |
| 52-week low | $4.91 | $0.7603 |
| Distance from 52-week high | -76.77% | -82.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +1022.75% | +2053.32% |
| Average volume | 55.52K | 180.42K |
| Shares outstanding | 1.80M | 14.94M |
| Employees | 1 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed LTRN by 871.9 percentage points over the past year.
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
GTBP vs LTRN FAQ
Which is bigger, GT Biopharma or Lantern Pharma?
Lantern Pharma (LTRN) is larger, with a market capitalization of $12.14M compared with $12.05M for GT Biopharma (GTBP).
Which stock has performed better over the past year, GTBP or LTRN?
GTBP returned +789.48% over the past 12 months, compared with -82.41% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are GT Biopharma and Lantern Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.